摘要
目的通过对住院患者应用利伐沙班进行房颤治疗的分析,探讨利伐沙班在使用中的药物相关性问题(DRPs),为临床合理用药提供参考依据。方法通过医院信息管理系统,抽取南京医科大学附属老年医院病例数共103例。采用国际通用的Granada-Ⅱ分类法,分别从必要性问题、有效性问题、安全性问题三个层面进行评价。结果103例患者中,有53例(51.45%)患者发生DRPs,共61例次,其中DRP4发生29例次(47.54%)、DRP5发生28例次(45.90%)、DRP6发生4例次(6.55%)。结论利伐沙班用于治疗75岁以上老年非瓣膜性房颤的主要问题为安全性和有效性。在临床使用上应加强DRPs的干预,促进临床对利伐沙班的合理使用。
OBJECTIVE By analyzing the data of rivaroxaban in inpatients,the drug correlation problems of rivaroxaban(DRPS)were discussed,aiming to provide a reference for the rational clinical drug use.METHODS Through the hospital information management system,a total of 103 cases were extracted from Geriatric Hospital of Nanjing Medical University Using the international Granada-classification,the above cases were evaluated from the aspects of necessity problem,effectiveness problem,and safety problem.RESULTS Of the 103 patients included,53(51.45%)patients had DRPs in 61 cases,including 29(47.54%)of DRP4,28(45.90%)of DRP5,and 4(6.55%)of DRP6(6.55%).CONCLUSION The main problems of rivaroxaban in the treatment of non-valvular AF in elderly over 75 years were safety and efficacy.The intervention of DRPs should be strengthened to promote the rational use of rivaroxaban in clinical practice.
作者
智俊娜
吴玲
谈震
刘莎
曲国红
ZHI Jun-na;WU Ling;TAN Zhen;LIU Sha;QU Guo-hong(Department of Pharmacy,Geriatric Hospital of Nanjing Medical University,Nanjing 210024,China;Kangda College of Nanjing Medical University,Lianyungang 222000,China)
出处
《海峡药学》
2025年第11期52-56,共5页
Strait Pharmaceutical Journal
基金
江苏省药学会-A201710。
